Cemil AYDIN, Mehmet Murat BAYKAM, Aykut BAŞER, Bilal ÇELİKÖRS, Hülya YILMAZ BAŞER, Okan ALKIŞ

PSA SEVIYESI 4-10 NG/ML OLAN HASTALARDA ALT ÜRINER SISTEM SEMPTOMLARI PROSTAT ADENOKANSER VE BENING PROSTAT HIPERPLAZISINI ÖN GÖREBILIR MI?

AMAÇ: Bu çalışmada PSA seviyesi 4-10 ng/mL olan hastalardaalt üriner sistem semptomalarının prostat adenokanser ve benignprostat hiperplazisini ön görecek bir parametre olup olmadığınıaraştırmayı amaçladık.GEREÇ VE YÖNTEMLER: 01 Haziran 2019 - 01 Şubat 2020 tarihleriarasında PSA değeri 4-10 ng/ml olan ilk kez TRUS-Bx uygulanan 75hasta prospektif olarak çalışmaya dahil edildi. Hastaların yaş, vücutkitle indeksi, PSA, Prostat hacmi, PSA dansitesi, uluslararası prostatsemptom skorları ve uluslararası erektil fonksiyon skorları kayıtedildi. Patoloji sonucuna göre grup 1 (benign prostat hiperplazisi)ve grup 2 (prostat adenokanser) olarak hastalar 2 gruba ayrılarakbelirtilen parametreler ile ilişkisi araştırıldı.BULGULAR: PSA değeri 4-10 ng/ml olan ilk kez TRUS-Bxuygulanan 75 hastanın patoloji sonucunda; 57 (%76) hastadabenign prostat hiperplazisi (Grup 1), 18 (%24) hastada prostatadenokanser (Grup 2) saptandı. İncelenen parametrelerden sadeceparmakle rektal muayenede pozitiflik (sertlik) bulgusu ve IPSS skordüşüklüğü Grup 2’de, Grup 1’e göre istatistiksel anlamlı farklılıksaptandı (sırası ile; p=0.001 ve p=0.022). Yapılan korelasyon analiziile de bulgular teyit edildi.SONUÇ: PSA 4-10 ng/mL olan hastalar için IPSS skor düşüklüğü,parmakla rektal muayenede pozitiflik (sertlik) olması kansersaptanma ihtimalini arttırmaktadır.

CAN LOWER URINARY TRACT SYMPTOMS PREDICT PROSTATE ADENOCARCINOMA AND BENING PROSTATIC HYPERPLASIA IN PATIENTS WITH A PSA LEVEL OF 4-10 NG/ML?

AIM: In this study, we aimed to investigate whether lower urinary tract symptoms are a parameter to predict prostate adenocarcinoma and bening prostatic hyperplasia in patients with a PSA level of 4-10 ng / mL. MATERIAL AND METHODS: 75 patients who were administered TRUS-Bx for the first time with a PSA value of 4-10 ng / ml between 01 June 2019 and 01 February 2020 were included prospectively. Age, body mass index, PSA, Prostate volume, PSA density, international prostate symptom scores and international index of erectile function scores of the patients were recorded. According to the pathology results, patients as Group 1 (bening prostatic hyperplasia) and Group 2 (prostate adenocarcinoma) were divided into two groups and their relationship with the specified parameters was investigated. RESULTS: As a result of the pathology of 75 patients who had TRUS-Bx for the first time with a PSA value of 4-10 ng / ml; Bening Prostate Hyperplasia (Group 1) was detected in 57 (76%) patients, and Prostate Adenocarcinoma (Group 2) in 18 (24%) patients. Among the parameters examined, only the stiffness in digital rectal examination finding and IPSS score low were statistically significant in Group 2 compared to Group 1 (respectively; p=0.001 ve p=0.022). In the correlation analysis, the findings were confirmed. CONCLUSION: For patients with PSA 4-10 ng/mL, low IPSS score and positive rectal examination (stiffness) increase the chance of cancer detection.

PDF

___

1.)Louie KS, Seigneurin A, Cathcart P, et al. Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis. Ann Oncol 2015;26:848-64. https://doi.org/10.1093/annonc/mdu525
2.)Pająk A, Borówka A. Prevalence of lower urinary tracts symptoms in the polish nonurban men at age 50–79 years. The first Polish community – based study. Urol Pol. 1998; Supl 1a: 10-11.
3.)Taylor BC, Wilt TJ, Fink HA, et al. Prevalence, severity, and health correlates of lower urinary tract symptoms among older men: the MrOS study. Urology. 2006; 68: 804-9. https://doi.org/10.1016/j.urology.2006.04.019
4.)Young JM, Muscatello DJ, Ward JE. Are men with lower urinary tract symptoms at increased risk of prostate cancer? A systematic review and critique of the available evidence. BJU Int. 2000; 85: 1037-48. https://doi.org/10.1046/j.1464-410x.2000.00659.x
5.)Brown CT, O'Flynn E, Van Der Meulen J, et al. The fear of prostate cancer in men with lower urinary tract symptoms: should symptomatic men be screened? BJU Int. 2003; 91: 30-32. https://doi.org/10.1046/j.1464-410x.2003.04013.x
6.)Dobruch J, Modzelewska E, Tyloch J, et al. Lower urinary tract symptoms and their severity in men subjected to prostate biopsy. Cent European J Urol 2014; 67: 177-81. https://doi.org/10.5173/ceju.2014.02.art11
7.)Meigs JB, Barry MJ, Oesterling JE, et al. Interpreting results of prostate–specific antigen testing for early detection of prostate cancer. J Gen Intern Med. 1996; 11: 505-12. https://doi.org/10.1007/bf02599596
8.)Lu CH, Lin TP, Shen SH, et al. Clinical efficacy of transrectal ultrasound-guided prostate biopsy in men younger than 50 years old with an elevated prostate-pecific antigen concentration (>4.0 ng/mL). Journal of the Chinese Medical Association 2017;80:413-8. https://doi.org/10.1016/j.jcma.2016.07.007
9.)Frånlund M, Carlsson S, Stranne J, et al. The absence of voiding symptoms in men with a prostate–specific antigen (PSA) concentration of ≥3.0 ng/ml is an independent risk factor for prostate cancer: results from the Gothenburg Randomized Screening Trial. BJU Int. 2012; 110: 638-43. https://doi.org/10.1111/j.1464-410X.2012.10962.x
10.)Juszczak K. The presence of LUTS is not a decisive tool for deciding who should be qualified for prostate biopsy. Cent European J Urol 2014; 67: 182-3. https://doi.org/10.5173/ceju.2014.02.art12
11.)Cicione A, Cormio L, Cantiello F, et al. Presence and severity of lower urinary tract symptoms are inversely correlated with the risk of prostate cancer on prostate biopsy. Minerva Urologica e Nefrologica 2017;69:486-92. https://doi.org/10.23736/S0393-2249.17.02737-0.